Baker McKenzie advised Ariceum Therapeutics (Ariceum) on the successful completion of a EUR 25 million Series A financing round, co-led by EQT Life Sciences (formerly LSP) and HealthCap. and on an asset acquisition from Ipsen Pharma.
Ariceum Therapeutics (Ariceum) is a private biotech company developing a novel, first in class radiopharmaceutical product for the diagnosis and targeted radiotherapy of certain hard-to-treat cancers. The company was co-founded by EQT Life Sciences (formerly LSP) and HealthCap which also co-led the oversubscribed financing round that was joined by Pureos Bioventures. Ipsen transferred assets, and all rights to these, into the Company
"Together with our client and our team of specialized corporate, biotechnology and life sciences lawyers, we were
able to successfully secure funds and pave the way for developing a treatment for patients suffering from certain hard-to-treat cancers," comments Julia Braun, LL.M., lead partner on the transaction.
Ariceum is led by a highly experienced management team with a strong track record and expertise in clinical trials, systemic radiation therapy and radiopharmaceutical development, as well as launching and commercialising diagnostic and therapeutic products in a variety of indications worldwide.
Baker McKenzie's Corporate / M&A and life science teams regularly advise pharma companies, financial and strategic investors and early stage biotech companies on domestic and international healthcare transactions.
Most recently, Baker McKenzie advised Andera Partners, Evotec and Fund+ on a EUR 60 million Series B financing of Tubulis GmbH, Allecra Therapeutics on an exclusive license and supply agreement with ADVANZ PHARMA, MODAG on a strategic collaboration with Teva, Chord Therapeutics on its sale to Merck KGaA, LSP as lead investor on a EUR 20 million Series A Equity Financing in Innovative Molecules, Numab Therapeutics on a CHF 100 million Cross Over Financing, CatalYm on a EUR 50 million Series B financing led by Vesalius Capital, Casdin Capital on a USD 50 million extension of the Series B Equity Financing in DNA Script, and Chr. Hansen Holding on the acquisition of Jennewein Biotechnologie.
Legal advisor to Ariceum Therapeutics:
Corporate/M&A: Julia Braun, LL.M. (partner, Munich)
Corporate/M&A: Marcus Meese (partner, Munich), Katja Heuterkes (counsel, Munich), Julia Rossié (associate, Munich)
Employment: Matthias Köhler (partner, Berlin), Felix Arnold, Harasch Yakubi (both associates, Berlin), Amelie Czekalla (associate, Frankfurt)
IP: Markus Hecht (counsel, Frankfurt)
Tax: Thomas Gierath (partner, Munich), Viktoria Ritter (associate, Munich), Jochen Meyer-Burow (partner, Frankfurt), Ariane Schaaf (counsel, Frankfurt)